The Duluth CCOP, established and funded by the National Cancer Institute (NCI) in 1984 and refunded in 1987, 1990, 1995, and 2000, is the only program of its kind in northern Minnesota and Northern Wisconsin. The Duluth CCOP is comprised of physicians and ancillary support staff who practice under the umbrella of the St. Mary's Duluth Clinic Health System (SMDC) in three institutions in Duluth, MN: the Duluth Clinic Cancer Center (DCCC), St. Mary's Medical Center, and Miller Dwan Medical Center. Hematology/Oncology clinics are also served by DCCC hematologists/oncologists at various regional outreach sites throughout the catchment area. Geographically, the Duluth CCOP covers a large area including urban and rural areas. The CCOP brings the benefits of clinical research to patients in a region that would be without access to clinical trials due to the distance to the nearest comprehensive cancer center. The strategy of the CCOP is to provide patients in the region access to state-of-the-art cancer care through participation in treatment and cancer control protocols and increase accrual to cancer prevention and control protocols. NCCTG will continue to function as the primary research base of the CCOP and secondary research bases will be Eastern Cooperative Oncology Group, National Surgical Breast and Bowel Program, Children's Oncology Group, American College of Surgeons Oncology Group, and the Comprehensive Cancer Center of Wake Forest University CCOP research base. The goal of the CCOP is accrue 200 patient credits to treatment protocols and 310 patient credits to prevention/cancer control protocols per year. By virtue of the already established programs and the commitment to quality, it is believed that a high level of productivity and quality can be maintained.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035269-26
Application #
7656677
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1983-09-01
Project End
2010-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
26
Fiscal Year
2009
Total Cost
$747,046
Indirect Cost
Name
Duluth Clinic, Ltd.
Department
Type
DUNS #
361078798
City
Duluth
State
MN
Country
United States
Zip Code
55805
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Dy, Grace K; Molina, Julian R; Qi, Yingwei et al. (2014) NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 9:1146-53
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83

Showing the most recent 10 out of 172 publications